Adaptimmune Therapeutics PLC
ADAP0.055USD
0.0000.00%
종가 03/30, 16:00（ET）시세는 15분 지연됩니다
87.31M시가총액
손실P/E TTM
자세한 내용은 Adaptimmune Therapeutics PLC 회사
Adaptimmune Therapeutics PLC is focused on pre-clinical programs, including PRAME and CD70-directed T-cell therapies, and its allogeneic pipeline. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). It is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Adaptimmune Therapeutics PLC 정보
종목 코드 ADAP
회사 이름Adaptimmune Therapeutics PLC
상장일May 06, 2015
CEORawcliffe (Adrian George)
직원 수506
유형Depository Receipt
회계 연도 종료May 06
주소60 Jubilee Avenue
도시ABINGDON
증권 거래소NASDAQ Capital Market Consolidated
국가United Kingdom
우편 번호OX14 4RX
전화441235430000
웹사이트https://www.adaptimmune.com/
종목 코드 ADAP
상장일May 06, 2015
CEORawcliffe (Adrian George)
Adaptimmune Therapeutics PLC의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Priti Hegde, Ph.D.
Dr. Priti Hegde, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+65.65%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sun, Mar 29
마지막 업데이트: Sun, Mar 29
주주
주주 유형
주주
주주
비율
Alpha Architect, LLC
0.30%
Menzel (Garry E)
0.23%
Rathbones Investment Management Limited
0.16%
Rawcliffe Adrian
0.15%
XTX Markets LLC
0.13%
기타
99.02%
주주
주주
비율
Alpha Architect, LLC
0.30%
Menzel (Garry E)
0.23%
Rathbones Investment Management Limited
0.16%
Rawcliffe Adrian
0.15%
XTX Markets LLC
0.13%
기타
99.02%
주주 유형
주주
비율
Individual Investor
0.63%
Investment Advisor
0.33%
Investment Advisor/Hedge Fund
0.21%
Venture Capital
0.13%
Research Firm
0.02%
기타
98.68%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
165
42.25M
57.79%
-8.12K
2025Q3
183
42.26M
58.51%
-57.25M
2025Q2
189
116.07M
65.05%
-1.37M
2025Q1
186
117.46M
62.78%
-44.42M
2024Q4
186
127.90M
58.86%
-11.67M
2024Q3
189
154.60M
64.35%
-2.20M
2024Q2
192
156.54M
67.34%
-7.97M
2024Q1
203
164.83M
67.18%
-6.80M
2023Q4
199
145.59M
71.95%
-5.54M
2023Q3
217
150.77M
70.44%
+3.59M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Alpha Architect, LLC
800.00K
0.3%
--
--
Sep 30, 2025
Menzel (Garry E)
611.22K
0.23%
+401.29K
+191.15%
Apr 11, 2025
Rathbones Investment Management Limited
432.82K
0.16%
--
--
Sep 30, 2025
Rawcliffe Adrian
395.23K
0.15%
+219.59K
+125.03%
Apr 11, 2025
Bertrand William C Jr
198.89K
0.07%
+59.86K
+43.05%
Apr 11, 2025
Lunger (John)
170.89K
0.06%
+59.86K
+53.91%
Apr 11, 2025
Norry (Elliot)
133.26K
0.05%
+66.41K
+99.32%
Apr 11, 2025
Piccina (Cintia)
111.07K
0.04%
+94.24K
+559.70%
Apr 11, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
ActivePassive International Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ActivePassive International Equity ETF
비율0%
Fidelity Enhanced Small Cap ETF
비율0%
SPDR S&P International Small Cap ETF
비율0%
Invesco NASDAQ Future Gen 200 ETF
비율0%
SPDR Portfolio Developed World ex-US ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
